{"id":"csii-vildagliptin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vildagliptin inhibits DPP-4, an enzyme that degrades incretin hormones (GLP-1 and GIP), thereby prolonging their action to stimulate glucose-dependent insulin secretion and suppress glucagon. When combined with CSII (insulin pump therapy), this dual approach provides both exogenous insulin delivery and enhanced endogenous insulin secretion, improving glycemic control in type 2 diabetes patients.","oneSentence":"CSII (continuous subcutaneous insulin infusion) combined with vildagliptin, a DPP-4 inhibitor, delivers insulin continuously while enhancing endogenous insulin secretion by inhibiting dipeptidyl peptidase-4.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:29:28.950Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus (in combination with continuous subcutaneous insulin infusion)"}]},"trialDetails":[{"nctId":"NCT03958591","phase":"PHASE4","title":"Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification","status":"UNKNOWN","sponsor":"Yanbing Li","startDate":"2019-05-01","conditions":"Diabetes type2","enrollment":274},{"nctId":"NCT03563794","phase":"PHASE4","title":"Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2018-06-10","conditions":"T2DM","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"CSII+Vildagliptin","genericName":"CSII+Vildagliptin","companyName":"The First Affiliated Hospital of Xiamen University","companyId":"the-first-affiliated-hospital-of-xiamen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CSII (continuous subcutaneous insulin infusion) combined with vildagliptin, a DPP-4 inhibitor, delivers insulin continuously while enhancing endogenous insulin secretion by inhibiting dipeptidyl peptidase-4. Used for Type 2 diabetes mellitus (in combination with continuous subcutaneous insulin infusion).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}